Suppr超能文献

脂质体-p53复合物区域给药对早期支气管内癌的有效治疗

Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes.

作者信息

Zou Y, Zong G, Ling Y H, Hao M M, Lozano G, Hong W K, Perez-Soler R

机构信息

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77054, USA.

出版信息

J Natl Cancer Inst. 1998 Aug 5;90(15):1130-7. doi: 10.1093/jnci/90.15.1130.

Abstract

BACKGROUND

Lung cancer originates in a diffusely damaged bronchial epithelium as a result of sequential and cumulative genetic alterations. We investigated the feasibility of in vivo gene replacement in endobronchial precancerous and cancerous cells by a regionally administered nonviral delivery system.

METHODS

After evaluating the in vitro transfection efficiency and cytotoxicity of a variety of cationic liposome-p53 formulations, a specific formulation, DP3-p53, was selected for further in vitro and in vivo evaluation. The ability of DP3-p53 to introduce the p53 gene in the normal bronchial epithelium was studied in transgenic mice that lack the p53 gene. The therapeutic effect of DP3-p53 administered intratracheally was studied in two nude mouse models of endobronchial human lung cancer by use of H358 (p53-null) and H322 (p53-mutant) cells.

RESULTS

DP3-p53 was able to effectively introduce and express the p53 gene and induce G1 arrest and apoptosis in H358 cells in vitro and to introduce and transcribe the p53 gene in the bronchial epithelium of transgenic mice that lack the p53 gene in vivo. In therapeutic experiments using groups of four or five mice each, administration of five intratracheal doses of DP3-p53 (2 microg or 8 microg DNA per dose) on days 4, 8, 12, 16, and 20 after intratracheal tumor inoculation significantly inhibited lung tumor formation and prolonged by approximately twofold the survival of mice bearing H358 or H322 endobronchial tumor cells in contrast to the survival among untreated mice and mice treated with the DP3-empty vector (P = .007 [two-sided logrank test] for mice bearing H358 cells and P = .008 [two-sided logrank test] for those bearing H322 cells).

CONCLUSIONS/IMPLICATIONS: Liposome-based p53 delivery through the airways is a potentially effective strategy for the treatment of early endobronchial cancer. These results have important implications for the gene therapy and prevention of human lung cancer.

摘要

背景

肺癌起源于因一系列累积性基因改变而广泛受损的支气管上皮。我们研究了通过局部给药的非病毒递送系统在支气管内癌前细胞和癌细胞中进行体内基因替代的可行性。

方法

在评估了多种阳离子脂质体-p53制剂的体外转染效率和细胞毒性后,选择了一种特定制剂DP3-p53进行进一步的体外和体内评估。在缺乏p53基因的转基因小鼠中研究了DP3-p53在正常支气管上皮中导入p53基因的能力。通过使用H358(p53缺失)和H322(p53突变)细胞,在两种支气管内人肺癌裸鼠模型中研究了气管内给予DP3-p53的治疗效果。

结果

DP3-p53能够在体外有效地导入并表达p53基因,诱导H358细胞中的G1期阻滞和凋亡,并且在体内能够在缺乏p53基因的转基因小鼠的支气管上皮中导入并转录p53基因。在每组四或五只小鼠的治疗实验中,在气管内接种肿瘤后的第4、8、12、16和20天给予五次气管内剂量的DP3-p53(每剂量2微克或8微克DNA),与未治疗的小鼠和用DP3空载体治疗的小鼠相比,显著抑制了肺肿瘤的形成,并使携带H358或H322支气管内肿瘤细胞的小鼠的生存期延长了约两倍(携带H358细胞的小鼠,双侧对数秩检验P = 0.007;携带H322细胞的小鼠,双侧对数秩检验P = 0.008)。

结论/启示:通过气道基于脂质体递送p53是治疗早期支气管内癌的一种潜在有效策略。这些结果对人类肺癌的基因治疗和预防具有重要意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验